Article Information
History
- December 16, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Cyrielle Hou, PharmD, PhD1,
- Baptiste Periou, MS1,3,
- Marianne Gervais, PharmD, PhD1,
- Juliette Berthier1,
- Yasmine Baba-Amer1,
- Sarah Souvannanorath, MD3,
- Edoardo Malfatti, MD1,2,3,
- Fréderic Relaix, PhD1,
- Maximilien Bencze, PhD*,1 and
- François Jérôme Authier, MD, PhD1,2,3,*,✉
- 1Univ Paris Est Créteil, INSERM, IMRB, F-94010 Créteil, France
- 2Reference Centre for Neuromuscular Diseases “Nord-Est-Ile de France”, FILNEMUS, France
- 3AP-HP, Hôpital Mondor, Service d’histologie, F-94010 Créteil, France
- ↵✉Corresponding author: francois-jerome.authier{at}aphp.fr
↵* Equal contribution
Author Contribution CH designed, performed all in vitro and in vivo experiments, and analyzed results. BP performed macro analysis and help with several experiments. MGT performed in vivo experiments. JB, MGT performed muscle clearing and analyzed them. YBA contributed to human muscle sample processing. FJA, SS, and EM performed muscle biopsies. FJA checked clinical and histopathological data for included patients.
FJA and MB designed and supervised the project and oversaw experiments. CH and FJA wrote the manuscript. BP, MB, MGT, EM, SS and FR read and edited the manuscript. CH, FJA, FR obtained funding.
All authors were involved in revising it critically for important intellectual content.
Posted December 16, 2021.
Interferon-gamma mediates skeletal muscle lesions through JAK/STAT pathway activation in inclusion body myositis
